Journal of Drugs in Dermatology articles from March 2006

Journal of Drugs in Dermatology archives from March 2006

Erratum.(Correction notice)
March 1, 2006... In the February issue of the JDD, the author of "A Comprehensive Review of Imatinib Mesylate (Gleevec) for Dermatological Diseases" was Noah Scheinfeld MD.

Crusted scabies: a clinical review.
March 1, 2006... Abstract Crusted scabies, a rare variant of classical scabies, is a highly contagious condition in which the skin is infected with thousands to millions of mites. It can be defined as a generalized severe scabies infestation usually...

Imatinib mesylate and dermatology Part 2: a review of the cutaneous side effects of imatinib mesylate.
March 1, 2006... Abstract Cutaneous reactions to imatinib are common and occur in 9.5% to 69% of patients depending on the series reported. Maculopapular eruptions, erythematous eruptions, edema, and periorbital edema are the most common adverse events...

Combination topical therapy for the treatment of psoriasis.
March 1, 2006... Abstract Dermatological research continues to move toward the goal of developing an effective psoriasis treatment that would rapidly clear lesions and provide long-term freedom from visible signs and symptoms. Currently, topical...

A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair[TM]) in the management of mild to moderate atopic dermatitis in adults.
March 1, 2006... Abstract Background: MAS063DP cream has received marketing authorization in the US and the European Union for symptom relief of atopic dermatitis (eczema) and contact dermatitis. Design: A multicenter, randomized, vehicle-controlled,...

Esophagitis due to tetracycline and its derivatives in dermatology patients.
March 1, 2006... Abstract Medication induced esophagitis (MIE) has been reported in dermatology patients taking tetracycline antibiotics. The symptoms of esophagitis, preventable with proper instruction, can create morbidity and lead to increased costs for...

Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients.
March 1, 2006... Abstract Background: Infliximab inhibits T-cell activation by binding tumor necrosis factor-[alpha] (TNF-[alpha]). This medication is widely used in the US for treatment of psoriasis as an off-label indication. The durability of its effect...

Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
March 1, 2006... Abstract Topical retinoids offer highly effective treatment for both inflammatory and non-inflammatory acne, with tazarotene demonstrating greater efficacy than other topical retinoids. A multicenter, double-blind, randomized,...

Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in alopecia areata and factors influencing the outcome.
March 1, 2006... Abstract Background: Immunotherapy with sqauric acid dibutyl ester (SADBE) is a well-accepted therapy for alopecia areata. Objective: To study efficacy, safety, and factors influencing the outcome in the treatment of alopecia areata....

Gel vehicles are not inherently more irritating than creams.
March 1, 2006... Abstract Background: It has been thought that topical gels are inherently more irritating than topical creams. Nevertheless, the irritancies of topical products are potentially quite variable, and a priori assumptions about relative...

Cutaneous effects of sirolimus in renal transplant recipients.
March 1, 2006... Abstract Cancer is a major cause of death in immunosuppressed transplant patients. Therefore, sirolimus is frequently used in these patients for its immunosuppressive and antineoplastic properties. However, a variety of cutaneous side...

Primary cutaneous nodular amyloidosis in a patient with Sjogren's syndrome.(CASE REPORTS)
March 1, 2006... Abstract A 71-year-old woman with a history of Sjogren's syndrome presented for evaluation of a waxy nodule present on the scalp for 6 months. Histopathologic examination revealed deposition of homogenous eosinophilic material throughout...

A case of an adverse reaction to topical 5-fluorouracil in irradiated skin.(CASE REPORTS)
March 1, 2006... Abstract A 73-year-old Caucasian male was treated in the dermatology clinic for squamous cell carcinoma (SCC) of the scalp by Mohs micrographic surgery. The patient subsequently received radiation therapy because of possible calvarium...

Serum sickness-like reaction to pamabrom.(CASE REPORTS)
March 1, 2006... Abstract Pamabron is a common over-the-counter diuretic used for relief of menstrual-associated symptoms. An urticarial eruption, with systemic complaints consistent with a serum sickness-like reaction, attributed to Pamabron is described....

Amantadine-induced livedo reticularis: a report of two cases.(CASE REPORTS)
March 1, 2006... Abstract In the last several years, amantadine has been increasingly prescribed for akinesia in Parkinson's disease and to combat fatigue associated with multiple sclerosis. Amantadine is a well-known medication involved in drug-induced...

The treatment of progressive pigmented purpura with ascorbic acid and a bioflavonoid rutoside.(CASE REPORTS)
March 1, 2006... Abstract Progressive pigmented purpura (PPP) is a group of dermatoses that are benign and usually self-limited. However, they may persist for months or years with frequent recurrences. Numerous treatments have been tried, but no effective...

Laser skin tightening: non-surgical alternative to the face lift.(LASER AND COSMETIC NEWS)
March 1, 2006... The drive for cosmetic enhancement of facial skin with minimal risk and rapid recovery has inspired nonsurgical means of wrinkle and photodamage reduction through laser skin resurfacing. Since its inception in the 1980s and early 1990s, laser...

Efficacy of gabapentin in the management of pruritus of unknown origin.(WASHINGTON WHISPERS)
March 1, 2006... Efficacy of Gabapentin in the Management of Pruritus of Unknown Origin Yesudian PD, et al. Archives of Dermatology. 2005;141:1507-1509. Summary The authors present 2 cases of generalized pruritus of unknown origin treated with...

Treatment of recalcitrant atopic dermatitis with omalizumab.(WASHINGTON WHISPERS)
March 1, 2006... Treatment of Recalcitrant Atopic Dermatitis with Omalizumab. Lane JE, MD, et al. Journal of the American Academy of Dermatology. 2006;54:68-72. Summary The authors present a case series of 3 patients with recalcitrant atopic...

Alefacept for alopecia areata.(WASHINGTON WHISPERS)
March 1, 2006... Alefacept for Alopecia Areata Heffernan MP, MD, et al. Archives of Dermatology. 2005;141:1513-1516. Summary The authors present 4 patients with alopecia areata or alopecia universalis treated with alefacept. Patients were treated...

Phase II clinical trial of MRE0094 for treatment of diabetic foot ulcers.(PIPELINE PREVIEWS)
March 1, 2006... King pharmaceuticals recently announced the initiation of a Phase II clinical trial for the topical drug MRE0094 for the treatment of chronic, neuropathic, diabetic foot ulcers. MRE0094 is an adenosine A2A receptor agonist that regulates the...

Sculptra for treatment of acne scars and varicella scars.(PIPELINE PREVIEWS)
March 1, 2006... Dermik Laboratories' Sculptra (injectable poly-L-lactic acid), which has FDA approval for correction of facial lipoatrophy in individuals with HIV, will be evaluated in a clinical study for its ability to treat acne and varicella (chicken pox)...

Smallpox vaccine study demonstrates promising results.(PIPELINE PREVIEWS)
March 1, 2006... CytoGenix, Inc., recently announced preliminary positive results for their technique for generating synthetic DNA vaccines called synDNA as a smallpox vaccine. The resultant vaccine generated a sizeable immune response. These DNA vaccines are...

Successful completion of Phase I trial for CH-1504 in treatment of psoriasis.(PIPELINE PREVIEWS)
March 1, 2006... Chelsea Therapeutics International, Ltd., recently announced the completion of a Phase I trial for its drug, CH-1504. This oral medication has anti-inflammatory as well as anti-tumor properties. CH-1504 is an anti-folate compound that lacks the...

New Drug Application for Orapem submitted to the FDA.(PIPELINE PREVIEWS)
March 1, 2006... Replidyne, Inc., has submitted a New Drug Application to the FDA for Orapem (faropenem medoxomil), the first marketing approval submission for this drug. In addition to other conditions, this drug will be used to treat uncomplicated skin and...

FDA approves New Drug Application for Taclonex.(PIPELINE PREVIEWS)
March 1, 2006... The FDA recently approved the New Drug Application (NDA) for Taclonex, which was submitted by LEO Pharma. Taclonex is a topical ointment that is used to treat psoriasis in adult patients. The drug is a combination of calcipotriene 0.005% and...

FDA approves Desoximetasone Gel.(PIPELINE PREVIEWS)
March 1, 2006... The FDA recently approved The Perrigo Company's Desoximetasone Gel USP 0.05% for the treatment of inflammatory skin conditions. This drug is the AB-rated equivalent of Taro Pharmaceutical's Topicort Gel 0.05%. The Perrigo Company is the largest...

New data concerning the recently FDA approved drug Tygacil.(PIPELINE PREVIEWS)
March 1, 2006... Wyeth Pharmaceuticals recently presented data that support the in vitro activity of Tygacil (tigecycline) against many resistant Gram-negative bacteria, including Extended-Spectrum Beta-Lactamase (ESBL)-producing organisms. ESBLs are enzymes...

FDA approves updated black box warning label for Elidel and Protopic.(PIPELINE PREVIEWS)
March 1, 2006... The FDA recently announced that the labeling of both Elidel (pimecrolimus) and Protopic (tacrolimus) will be updated to include a black box warning concerning a possible risk of cancer. In addition, a Medication Guide will be given to patients...

Study shows Regranex (Becaplermin) gel effective in treatment of diabetic neuropathic foot ulcers.(PIPELINE PREVIEWS)
March 1, 2006... Johnson & Johnson recently announced results of a study concerning the effectiveness of Regranex (Becaplermin) Gel in the treatment of diabetic foot ulcers. Regranex (Becaplermin) gel 0.01% is a recombinant human platelet-derived growth factor...

Marketing approval in Europe granted to Cubicin.(PIPELINE PREVIEWS)
March 1, 2006... Chiron Corporation recently announced that Cubicin (daptomycin) was granted marketing approval by the European Commission. The FDA approved Cubicin in September of 2003 for the treatment of complicated skin and soft-tissue infections. Cubicin...

The effects of hypercapnia, supplemental oxygen, and dexamethasone on surgical wound infection.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified and sponsored by Outcomes Research Group. We will test the hypotheses that mild hypercapnia and supplemental oxygen reduce wound infection risk in patients undergoing colon resection. We...

Study evaluating etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified and Sponsored by Wyeth. This is an open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc...

A study of adalimumab to treat sarcoidosis of the skin.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified by Pariser, Robert J., M.D. Sponsors and collaborators: Pariser, Robert J., M.D., Abbott Laboratories, and Virginia Clinical Research, Inc. The purpose of this study is to determine...

Effect of garlic on inflammatory mediators.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified and sponsored by Albany Medical College. This research will investigate the effect of garlic oil extract when added to daily diet on inflammatory mediators and blood clotting...

Islet transplantation using efalizumab.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified by Emory University. Sponsors and Collaborators: Emory University, Juvenile Diabetes Research Foundation, and Genentech. Islet transplantation in type 1 diabetics with hypoglycemic...

Assessment of effectiveness and safety of Dysport[R] for the treatment of hemifacial spasm.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified and sponsored by Ipsen. To compare the effectiveness and safety of Dysport with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the...

Ramipril in rheumatoid arthritis.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified and sponsored by Sanofi-Aventis. The present study is designed to evaluate the hypothesis that the Angiotensin Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and...

Treatment of breast pain using a medication (diclofenac) applied to the skin.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified and sponsored by Mayo Clinic. This study is designed to determine whether topical diclofenac is effective for the treatment of breast pain. Condition Intervention ...

Combination chemotherapy in treating young patients with Langerhans cell histiocytosis.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified by National Cancer Institute (NCI). Sponsored by United Kingdom Children's Cancer Study Group. This randomized clinical trial is studying combination chemotherapy to see how well it works in...

VEGF-AS in treating patients with HIV-related Kaposi's sarcoma.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified by National Cancer Institute (NCI). Sponsors and collaborators: AIDS Associated Malignancies Clinical Trials Consortium and the National Cancer Institute (NCI). This phase I/II trial...

Topical agent for treatment of red skin.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified by Mayo Clinic. SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then...

Efficacy of adhesive tables in treating oral ulcers (aphthous).(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified by Hadassah Medical Organization. Sponsors and Collaborators: Hadassah Medical Organization Grant from "Axiomedic. Advanced Medical Solutions," Zurich, Switzerland. Participants in...

Wound Closure Techniques.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified and sponsored by Hartford Hospital. A Comparison of Skin Closure Techniques after Primary Cesarean Delivery. Condition Intervention Wounds, Closure Device: Dermabond Study ID Numbers:...

Efficacy and safety of two doses of liarozole vs. placebo for the treatment of lamellar ichthyosis.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified and sponsored by Barrier Therapeutics. The current study intends to evaluate the efficacy and safety in patients with lamellar ichthyosis. Condition Intervention ...

A pilot study of etanercept in dermatomyositis.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified and sponsored by National Institute of Neurological Disorders and Stroke (NINDS). The purpose of this study is to determine the safety and tolerability of etanercept in people with...

Use of infliximab for the treatment of pemphigus vulgaris.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Verified and sponsored by National Institute of Allergy and Infectious Diseases (NIAID). This study will determine if infliximab given in combination with prednisone is a safe and effective...

Soothe versus refresh.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified and sponsored by Pharmaceutical Research Network. To determine the ocular efficacy and safety of soothe and refresh tears. Condition Intervention Phase Condition ...

Use of etanercept in the treatment of moderate to severe lichen planus.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is not yet open for patient recruitment. Sponsors and Collaborators: Stanford University, UMDNJ-Robert Wood Johnson Medical School, Wright State University, University of Louisville, Wake Forest University, University of Michigan,...

A multicenter, open label Phase IIIb study of subcutaneously administered Raptiva in the treatment of adult patients with moderate to severe plaque psoriasis.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified and sponsored by Serono. Phase IIIb, open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered SC for 24 weeks....

Phase I and pharmacokinetic study of BAY 43-9006 (Sorafenib) in patients with Kaposi's sarcoma.(CLINICAL TRIAL REVIEW)
March 1, 2006... This study is currently recruiting patients. Verified by National Institutes of Health Clinical Center. Sponsored by: National Cancer Institute (NCI). This study is designed to test the toxicity and pharmacokinetics of different doses of BAY...